Using the experimental design described in the PET chapter, DW and DCE-MRI sequences were tested for their capacity in measuring the antiproliferative and antivascular effects of trastuzumab and for their sensitivity in identifying responsiveness in HER2+ breast cancer xenograft models. This evidence concerns the gene ERBB2 and breast cancer.